**Name of Journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 69087

**Manuscript Type:** META-ANALYSIS

**Systematic review and Meta-analysis of efficacy and safety of dienogest in treatment of endometriosis**

Lin SC *et al.* Meta-analysis of dienogest

Shao-Chong Lin, Xin-Yue Wang, Xi-Ling Fu, Wen-Hui Yang, Han Wu, Yang Bai, Zhong-Na Shi, Jun-Peng Du, Bao-Jin Wang

**Shao-Chong Lin, Xin-Yue Wang, Xi-Ling Fu, Yang Bai, Zhong-Na Shi, Bao-Jin Wang,** Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China

**Wen-Hui Yang,** Pharmacy Department, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China

**Han Wu,** Medical School of Zhengzhou University, Zhengzhou 450052, Henan Province, China

**Jun-Peng Du,** Department of Pediatric Surgery, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China

**Author contributions:** Lin SC, Wang BJ, and Du JP conceived and designed the study; Wang XY and Fu XL researched, extracted, and evaluated the data; Yang WH, Wu H, and Bai Y performed data analyses; Lin SC and Shi ZN wrote the manuscript; all authors read and approved the final manuscript.

**Supported by** the Science and Technology Department of Henan Province, No. 132300410352.

**Corresponding author: Bao-Jin Wang, PhD, Doctor,** Department of Gynecology, The Third Affiliated Hospital of Zhengzhou University, No. 7 Kangfu Front Street, Erqi District, Zhengzhou 450052, Henan Province, China. 2995269936@qq.com

**Received:** June 16, 2021

**Revised:** July 17, 2021

**Accepted:** August 20, 2021

**Published online:** August 28, 2021

**Abstract**

BACKGROUND

The quality of life of women with endometriosis is substantially adversely affected by the pelvic pain caused by this disease. However, the choice of medication for endometriosis remains controversial, and no drug has been clearly proven to be superior to others.

AIM

To assess the efficacy and safety of dienogest, a synthetic progestin, in the treatment of women with painful symptoms of endometriosis.

METHODS

PubMed, EMBASE, the Cochrane Library, and the Web of Science databases were searched from their inceptions to January 21, 2020 for randomized controlled trials (RCTs) that compared dienogest with other popular prescription drugs for the treatment of endometriosis. Two reviewers extracted the data. Mean difference (MD) values and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated.

RESULTS

Ultimately, seven RCTs with a total of 1493 participants met the requirements for this review. Dienogest was found to more effective than placebo in alleviating endometriosis-related pain (MD = -32.93, 95%CI: -44.63 to -21.23), but led to a more significant decline in plasma estradiol concentrations than placebo (MD = -44.7, 95%CI: -62.24 to -24.69). Dienogest was superior to gonadotropin-releasing hormone analogues (GnRH-a) in relieving pain (MD = -2.41, 95%CI: -3.58 to -1.24). Moreover, compared with dienogest, GnRH-a were significantly more likely to lead to the loss of bone mineral density (MD = 2.77, 95%CI: 0.16 to 5.37) and were significantly associated with a higher incidence of headaches (RR = 0.68, 95%CI: 0.52 to 0.91) and hot flushes (RR = 0.43, 95%CI: 0.18 to 1.02).

CONCLUSION

This meta-analysis demonstrated that dienogest may be a better pain-relief treatment for endometriosis patients, due to its high efficacy and tolerability.

**Key Words:** Dienogest; Gonadotrophin-releasing hormone analogues; Meta-analysis; Endometriosis; Medication

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Lin SC, Wang XY, Fu XL, Yang WH, Wu H, Bai Y, Shi ZN, Du JP, Wang BJ. Systematic review and Meta-analysis of efficacy and safety of dienogest in treatment of endometriosis. *World J Meta-Anal* 2021; 9(4): 377-388

URL: https://www.wjgnet.com/2308-3840/full/v9/i4/377.htm

DOI: https://dx.doi.org/10.13105/wjma.v9.i4.377

**Core Tip:** We comprehensively and systematically analyzed the safety and effectiveness of dienogest for the treatment of endometriosis-related pain. Only high-quality randomized controlled trials that compared dienogest with other drugs, such as gonadotrophin-releasing hormone analogues and placebo, were included in the meta-analysis. The results provide guidelines for the standardization of the clinical use of medications for endometriosis and would improve the choice of medications for patients.

**INTRODUCTION**

Endometriosis is defined as the presence of endometrial glands and stroma outside of the uterine cavity, and affects about 200 million women worldwide[1-3]. Although the pathogenesis of endometriosis remains unclear, it is generally accepted that its basic feature is the existence of ectopic endometrium. The chronic inflammatory reaction induced by ectopic endometrial lesions is the central process leading to endometriosis-related pain[4,5]. The resulting painful symptoms, such as dysmenorrhea, dyspareunia, and chronic pelvic pain, have a pronounced negative effect on quality of life and are the primary reason for which patients seek treatment[6,7]. Recent studies have emphasized the adverse effect of endometriosis symptoms on sexual function, work productivity, and psychological aspects of life[8]. The physical and mental suffering of patients is possibly due to the absence of sufficiently effective and targeted therapeutic methods.

The management of endometriosis has continuously improved, and a patient’s choice of treatment methods, such as medication, surgery, or assisted reproductive technology, usually depends on her age and fertility requirements[4]. Medication is the first-line therapeutic option for women who do not wish to conceive in the immediate future, considering that surgery has a high rate of recurrence and risk of complications and can reduce the ovarian reserve[1]. There are also many widely available pharmacological treatments for endometriosis, such as painkillers, non-steroidal anti-inflammatories (NSAIDs), combined oral contraceptives (COCs), progestins, and gonadotrophin-releasing hormone analogues (GnRH-a)[9,10]. Although each type of drug is widely used worldwide, they also have clear disadvantages. Additionally, no drug has been proven markedly superior to others.

Dienogest, a 19-nortestosterone and progesterone derivative, is a fourth-generation synthetic oral progestin that was designed to treat endometriosis. It binds highly selectively to progesterone receptors, thereby exerting potent progestogenic effects with little androgenic, mineralocorticoid, or glucocorticoid activity[11]. Crucially, dienogest suppresses the growth of endometrioid tissue and also exerts anti-inflammatory, antiproliferative, and antiangiogenic effects[12-14]. It has also shown good effectiveness and a favorable safety profile in long-term clinical application and follow-up studies. However, it remains uncertain whether dienogest is superior to other drugs.

The aim of this systematic review and Meta-analysis was to evaluate the efficacy and safety of dienogest for the treatment of endometriosis in women of reproductive age. We integrated and Meta-analyzed data from high-quality randomized controlled trials (RCTs) to assess differences between the treatment effects of dienogest and those of other drugs. This revealed strong evidence that dienogest should be the drug of first choice for treating endometriosis.

**MATERIALS AND METHODS**

***Search strategy***

To identify all relevant literature, a systematic search of the Cochrane Library, EMBASE, PubMed, and the Web of Science was conducted on January 21, 2020, using combinations of the following search terms: (endometriosis OR adenomyosis OR EMT OR EM OR uterine adenomyosis OR endometrioma) AND dienogest AND (placebo OR blank control OR drug). The search process and determination of eligibility were conducted independently by two investigators (Wang XF and Fu XL). Disagreements about eligibility or search criteria were mitigated through discussion with a third reviewer (Lin SC).

***Study selection***

We only included trials in which women had signs and symptoms of endometriosis or adenomyosis. Trials that met all of the following criteria were included: (1) Prospective RCTs; (2) English language studies; (3) patients in the experimental group were treated with dienogest, whereas those in the control group received other medications, such as GnRH-a, placebo, COCs, or NSAIDs; and (4) the primary outcome was an improvement in endometriosis-associated pain, and other outcomes included adverse effects and changes in clinical laboratory parameters.

Meta-analyses, reviews, case reports, conference abstracts, cohort studies, retrospective studies, and trials without available data were excluded. Studies involving adolescent or menopausal women were also excluded.

***Data extraction***

Two authors (Wang XF and Fu XL) independently extracted the data from the studies that met all of the inclusion criteria and none of the exclusion criteria. The data extracted were the first author’s name, the publication year, the study design, the interventions, the number of participants, and the inclusion criteria.

The primary efficacy outcome was a change in the visual analogue scale (VAS) scores of endometriosis-related pain before and after the trial, and the secondary efficacy outcome was a change in the number of analgesics administered. The outcomes used to evaluate safety were changes in bone mineral density (BMD) and estrogen concentration, the incidence of hot flushes and headaches, and the occurrence of other adverse events.

***Study quality***

To assess the quality of each included study, the Cochrane risk-of-bias assessment tool was used. Each type of risk was graded as low, high, or unclear for the included RCTs. Seven criteria related to the risk of bias were assessed in each study: (1) Random sequence generation; (2) allocation concealment; (3) blinding of participants and personnel; (4) blinding of outcome assessment; (5) incomplete outcome data; (6) selective reporting; and (7) other bias. Two authors (Wang XF and Fu X) independently assessed the risk of bias for each included study. Disagreements were resolved by discussion with a third reviewer (Lin SC).

***Statistical analysis***

Review Manager (RevMan) 5.3 software was used to conduct the Meta-analysis. Continuous data and dichotomous data are reported as the mean ± standard deviation (SDs) and the number of outcome events/total number, respectively. We also calculated the mean difference (MD) and 95% confidence intervals (CIs) of continuous data. Risk ratios (RRs) and 95%CIs were calculated for dichotomous data. *Q* tests and *I*2 statistics were applied to evaluate the heterogeneity in outcomes between studies. If there was no heterogeneity or *I*2 < 50%, a fixed-effect model was used to analyze the results. If *I*2 ≥ 50%, indicating the existence of high heterogeneity between studies, a random-effects model was used. Subgroup analysis was carried out according to the type of intervention. We also conducted a sensitivity analysis to find the source of heterogeneity. A funnel plot was used to assess publication bias. In all analyses, a *P*-value < 0.05 was considered statistically significant.

**RESULTS**

***Study selection and characteristics***

The search strategy identified 1028 trials. Initially, 385 duplicates were excluded, and a further 629 trials were excluded based on the title and/or abstract. The remaining 14 trials were further assessed by reading the full text.Four trials were excluded because randomization was not adopted in the grouping process[15-18]. One dose-ranging study was excluded because it did not compare dienogest with other treatments[19]. One trial’s detailed data were not provided, and it was also excluded as the author did not respond to a request for data[20]. One trial investigating the benefits of dienogest treatment before *in vitro* fertilization and embryo transfer was excluded, as it did not measure the specific outcomes analyzed in this meta-analysis[21]. Finally, seven RCTs with a high level of evidence were eligible for the analysis[22-28]. The procedure for study selection is presented in Figure 1.

Table 1 presents the characteristics of the studies included in this meta-analysis. The seven prospective RCTs included a total of 1493 women from ten countries: Germany, Italy, Ukraine, Austria, Spain, Poland, Portugal, Japan, China, and Egypt. Two milligrams of dienogest per day was the dosage in all studies. Efficacy was assessed in terms of changes in VAS scores for endometriosis-related pain and changes in the intake of supportive analgesic medication (SAM). Safety was assessed in terms of changes in BMD and serum estradiol (E2) concentrations, and the incidence of headaches and hot flushes. The results of quality assessment are shown in Figure 2. All eligible trials indicated a low risk of bias.

***VAS score for endometriosis-related pain***

All seven studies assessed the efficacy of dienogest in comparison with that of other drugs (placebo or GnRH-a) in terms of changes in VAS scores at the end of the treatment period. However, the data of one study were unclearly presented[26]. Our meta-analysis revealed a statistically significant advantage of dienogest, compared with other drugs, in terms of the relief of endometriosis- or adenomyosis-associated pain (MD = -17, 95%CI: -30.19 to -3.80). Considering the rather high heterogeneity between the studies [an *I*2 of 97% (*P* < 0.00001)], we conducted a subgroup analysis of the different categories of alternative drugs.

Dienogest was found to be significantly superior to GnRH-a for pain relief (MD = -2.41, 95%CI: -3.58 to -1.24) with a very low heterogeneity (*I*2 = 0.0%, *P* = 0.57). Dienogest was also significantly superior to placebo with respect to pain relief [MD = -32.93, 95%CI: -44.63 to -21.23], but with a high heterogeneity (*I*2 = 84%, *P* = 0.002) (Figure 3A). Subgroup analysis reduced the heterogeneity within each group but did not eliminate it. Therefore, we performed a sensitivity analysis by excluding each study, and then analyzing the effect of this exclusion. This revealed that the RCT performed by Lang *et al[*25] was the probable source of heterogeneity, as its elimination decreased *I*2 from 84% to 0.0%. The combined results of the other two articles also indicated that dienogest was superior to lacebo for pain relief (MD = -38.83, 95%CI: -45.17 to -32.49). Visual inspection of the funnel plot of the changes in VAS scores reveals its asymmetry, which suggests that there was some degree of publication bias and that more studies are needed to validate the results (Supplementary Figure 1).

***SAM intake***

Three studies that compared dienogest with placebo reported the change in the level of SAM intake, and the combined results indicated a significantly larger reduction of SAM intake in the dienogest group than the placebo group (MD = -0.39, 95%CI: -0.75 to -0.03), with an *I*2 of 72% (*P* = 0.03) (Figure 3B). Subgroup analyses of two studies (Osuga *et al*[27] and Lang *et al*[25])demonstrated a high heterogeneity, *i.e.*, a minimum *I*2 of 52%. The sensitivity analysis subsequent to removal of either of those studiesindicated that the statistical difference between dienogest and placebo was not significant (*P* = 0.08 and 0.24 for Osuga *et al*[27]and Lang *et al*[25], respectively). Thus, additional studies are required to validate this result.

***Change in BMD***

Three studies investigated the effect of dienogest on BMD, and we found that there was a statistically significant difference between dienogest and the other drugs with respect to changes in BMD. Two studies compared dienogest with GnRH-a, whereas one study compared dienogest with placebo. Therefore, a subgroup analysis was conducted based on the type of drug used as the control. A greater reduction in BMD was observed in the GnRH-a group than in the dienogest group (MD = 2.77, 95%CI: 0.16 to 5.37), but there was a significant heterogeneity between these two trials (*P* = 0.02, *I*2 = 80%). Furthermore, a smaller reduction in BMD was observed in the placebo group than in the dienogest group (MD = -0.71, 95%CI: -0.72 to -0.70) (Figure 4A).

***Change serum E2 concentrations***

Serum E2 concentrations were measured in three studies in which dienogest was compared with placebo. The E2 concentrations were lower in the dienogest groups than in the placebo groups. A Meta-analysis of the three studies showed that the decrease in the E2 concentration was -44.47 pg/mL [95%CI: -62.24 to -24.69]. The pooled measures revealed an *I*2 value of 0.0% (*P* = 0.78), indicating a homogeneity between studies (Figure 4B).

***Headache***

Headaches were one of the most common drug-related adverse effects reported during treatment. Four studies reported the incidence of headache after treatment: Three studies comparing dienogest with GnRH-a and one comparing dienogest with placebo. Their *I*2 of 31% (*P* = 0.23) indicated that there was a high heterogeneity between these studies. Therefore, the studies were divided into two subgroups according to the type of drug used in the control group. Women in the dienogest group were less likely to experience headaches than those in the GnRH-a group (RR = 0.68, 95%CI: 0.52 to 0.91), with *I*2 of 0.0% indicating that there was no heterogeneity between the studies in this group. The only RCT that compared dienogest with a placebo did not show a significant difference in the incidence of headaches (RR = 2.07, 95%CI: 0.75 to 5.74, *P* = 0.16) (Figure 5A).

***Hot flushes***

Three studies comparing dienogest with GnRH-a and one study comparing dienogest with placebo reported the incidence of hot flushes. Due to the high heterogeneity between these studies (*I*2 = 81%), we performed a subgroup analysis based on the type of drug used as the control. Only one study compared dienogest with placebo, reporting that the difference in the incidence of hot flushes was not statistically significant (RR = 4.86, 95%CI: 0.24 to 97.51).

The subgroup analysis showed that the incidence of hot flushes was greater in women treated with GnRH-a than in women treated with dienogest (RR = 0.43, 95%CI: 0.18 to 1.02; *I*2 = 86%, *P* = 0.0008) (Figure 5B). After excluding the study by Harada *et al*[22] from the sensitivity analysis, the *I*2 decreased from 86% to 39%. However, the combined results of the two remaining studies indicated that the difference between dienogest and GnRH-a with respect to the incidence of hot flushes was not statistically significant (*P* = 0.06). Given these conflicting results, more data are required to clarify the differences between the incidence of this adverse effect resulting from dienogest or GnRH-a treatment.

**DISCUSSION**

The chronic nature of endometriosis means that lifelong management must be the focus of clinical decision making, for which patients urgently need safer and more effective drugs. To comprehensively evaluate the efficacy and safety of dienogest in the treatment of endometriosis, we performed a Meta-analysis of seven RCTs that included a total of 1493 patients. The results showed that the pain-relieving ability of dienogest was superior to that of placebo and GnRH-a. Dienogest also exhibited significant safety advantages over GnRH-a, due to its low incidence of adverse effects. Taken together, these findings indicate that dienogest should be the first-line treatment for endometriosis.

The superior pain-relieving ability of dienogest may be attributable to the greater decrease in serum E2 concentrations observed in dienogest-treated patients than in those who received other treatments. This is consistent with the fact that a randomized, dose-controlled study indicated that a daily 2-mg dose of dienogest moderately suppresses E2 production and reliably inhibits ovulation[29], and that a moderate decrease in estrogen concentration effectively suppresses the growth of endometrial tissue and does not result in hypoestrogenic adverse effects, in accordance with the threshold theory proposed by Barbieri[30]. The patients’ dependence on supportive analgesics also decreased during treatment with dienogest, providing indirect evidence for the drug’s pain-relieving effect. In addition, in the safety analysis, no difference was observed in the incidence of headaches and hot flushes between the two groups. An extended study investigating the effects of dienogest treatment over 53 wk found that it induced a sustained reduction in endometriosis-associated pelvic pain, with low rates of treatment-related adverse events[31].

The superiority of dienogest over GnRH-a for relieving endometriosis-related pain was also supported by a -2.41 mm difference in VAS pain scores. In concordance with our findings, another meta-analysis concluded that dienogest was superior to GnRH-a in this regard, with a -2.17 mm difference in VAS pain scores[32]. Gerlinger *et al*[33] suggested a non-inferiority margin of 10 mm for endometriosis related pian measured using a VAS. Therefore, although the -2.41 mm difference in the VAS pain score is statistically significant, it is less than the suggested minimal clinically significant difference of 10 mm, and thus does not prove that dienogest is superior to GnRH-a in relieving endometriosis-related pain. However, the two drugs appear equivalent in terms of their pain-relieving ability, and more RCTs are required to confirm whether they clinically differ in this ability.

The safety of drugs used for the long-term management of endometriosis must not be overlooked. Dienogest showed significant safety benefits over GnRH-a, as the latter was more likely to lead to decreased BMD and an increased incidence of headaches and hot flushes. GnRH-a are an effective therapy for endometriosis, but they are also associated with hypoestrogenism and decreased BMD if taken for more than 6 mo. Patients are prescribed an add-back therapy to prevent this adverse event[34]. In contrast, dienogest can be taken for a long term with fewer adverse effects. A pooled analysis from four European RCTs confirmed the favorable safety and tolerability of dienogest in both short- and long-term use[35]. Thus, dienogest appears a better option for patients who require chronic treatment.

Research on the mechanism by which dienogest relieves the pelvic pain of endometriosis remains exploratory. Some researchers have found that dienogest can inhibit the production of tumor necrosis factor alpha and interleukin 1 beta by agonizing progesterone receptors, and ultimately inhibit the production of nerve growth factor, which has been shown to be an important factor in the pelvic pain of endometriosis[36-39]. It has also been suggested that the high efficacy of dienogest in relieving endometriosis pain is related to the expression of nuclear factor kappa-B (NF-κB) and Bcl-2, because dienogest can increase the activity of NF-κB and thus increase the apoptosis of endometrial mesenchymal cells[13,40]. Accordingly, a fuller understanding of the mechanism of action dienogest is required, as this may optimize its clinical applicability.

The main strength of this meta-analysis is that we only included RCTs with high levels of evidence, which included a total of 1493 patients, most of whom were clearly diagnosed by histology or laparoscopy. Second, our analysis of the safety and effectiveness of dienogest for the treatment of endometriosis was comprehensive and systematic. The results of this meta-analysis demonstrate how the clinical use of medications for endometriosis could be standardized and enhance patients’ ability to select the best treatment.

However, there are some limitations of our study. First, the included studies differed in the category of disease, the ethnicity of participants, the types of GnRH-a used for treatment, the administration route, and the duration of treatment, which may account for the heterogeneity between studies that we observed. For example, in analyzing the changes in BMD between the two studies, Gerlinger *et al*[32]attributed the heterogeneity observed between these studies to ethnicity. Moreover, estrogen plays a crucial role in the growth and maintenance of the skeleton, and Asian women have higher blood concentrations of estrogens than Caucasian women[41]. In addition, we conducted subgroup and sensitivity analyses to determine the sources of heterogeneity. Second, although the most frequent drug-related effect of dienogest in all included studies was irregular uterine bleeding (spotting and breakthrough bleeding), our safety assessments did not analyze this side effect. Although patients used daily diaries to record bleeding patterns in four of the included trials, these data cannot be used to accurately estimate the severity of bleeding. As such, an approach that can quantitatively evaluate irregular genital bleeding is needed to investigate this adverse effect. Third, our meta-analysis only included a small number of studies, and none compared dienogest with other therapies, such as compound COCs or levonorgestrel intrauterine devices, which have been proven effective in the treatment of endometriosis and adenomyosis. Finally, more studies are required to evaluate the pharmacoeconomics of drugs that are commonly used to treat endometriosis.

**CONCLUSION**

This Meta-analysis systematically evaluated the efficacy and safety of dienogest for the treatment of endometriosis. The results showed that dienogest is superior to placebo and GnRH-a in terms of pain relief and is better tolerated than GnRH-a. This demonstrates that dienogest may be the best medication for endometriosis patients seeking pain relief. Further high-quality RCTs are warranted to confirm these findings.

**ARTICLE HIGHLIGHTS**

***Research background***

Endometriosis is one of the common gynecological diseases in reproductive women and the concomitant pelvic pain has substantial negative effects on patients’ quality of life. In recent years, significant advances have been made in the treatment of endometriosis, and drugs remain the primary treatment option for women of childbearing age. However, there is no agreement on which drugs are most effective and tolerated for the treatment of endometriosis.

***Research motivation***

Several well-designed randomized controlled trials (RCTs) have demonstrated that dienogest is effective in relieving endometriosis-related pain and has a tolerable adverse-effect profile. However, these RCTs have not unambiguously demonstrated whether dienogest is superior to other drugs.

***Research objectives***

This study was conducted to evaluate the effectiveness and safety of dienogest compared with other drugs for the treatment of endometriosis.

***Research methods***

This meta-analysis only included RCTs that compared dienogest with other drugs in the treatment of endometriosis. Review Manager (RevMan) 5.3 software was used to calculate mean difference (MD) values and risk ratios (RRs) with 95% confidence intervals (CIs).

***Research results***

This study included seven RCTs with 1493 participants and demonstrated that dienogest was more effective than placebo in alleviating endometriosis-related pain (MD = -32.93, 95%CI: -44.63 to -21.23), and led to a more significant decrease in plasma estradiol concentrations than placebo (MD = -44.7, 95%CI: -62.24 to -24.69). The combined results showed that dienogest was superior to GnRH-a in relieving pain (MD = -2.41, 95%CI: -3.58 to -1.24). Furthermore, adverse events were more frequent in patients in the GnRH-a group, including the loss of BMD (MD = 2.77, 95%CI: 0.16 to 5.37), headaches (RR = 0.68, 95%CI: 0.52 to 0.91), and hot flushes (RR = 0.43, 95%CI: 0.18 to 1.02).

***Research conclusions***

Dienogest is an effective and tolerable therapeutic for the treatment of endometriosis-related pain in women of reproductive age.

***Research perspectives***

The results of this meta-analysis provide insights on how the clinical use of medications for endometriosis could be standardized and should improve the choice of medications for patients.

**REFERENCES**

1 **Chapron C**, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. *Nat Rev Endocrinol* 2019; **15**: 666-682 [PMID: 31488888 DOI: 10.1038/s41574-019-0245-z]

2 **Burney RO**, Giudice LC. Pathogenesis and pathophysiology of endometriosis. *Fertil Steril* 2012; **98**: 511-519 [PMID: 22819144 DOI: 10.1016/j.fertnstert.2012.06.029]

3 **Rogers PA**, D'Hooghe TM, Fazleabas A, Gargett CE, Giudice LC, Montgomery GW, Rombauts L, Salamonsen LA, Zondervan KT. Priorities for endometriosis research: recommendations from an international consensus workshop. *Reprod Sci* 2009; **16**: 335-346 [PMID: 19196878 DOI: 10.1177/1933719108330568]

4 **Bulun SE**, Yilmaz BD, Sison C, Miyazaki K, Bernardi L, Liu S, Kohlmeier A, Yin P, Milad M, Wei J. Endometriosis. *Endocr Rev* 2019; **40**: 1048-1079 [PMID: 30994890 DOI: 10.1210/er.2018-00242]

5 **Kennedy S**, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E; ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. *Hum Reprod* 2005; **20**: 2698-2704 [PMID: 15980014 DOI: 10.1093/humrep/dei135]

6 **Vercellini P**, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. *Nat Rev Endocrinol* 2014; **10**: 261-275 [PMID: 24366116 DOI: 10.1038/nrendo.2013.255]

7 **De Graaff AA**, D'Hooghe TM, Dunselman GA, Dirksen CD, Hummelshoj L; WERF EndoCost Consortium, Simoens S. The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey. *Hum Reprod* 2013; **28**: 2677-2685 [PMID: 23847114 DOI: 10.1093/humrep/det284]

8 **Young K**, Fisher J, Kirkman M. Women's experiences of endometriosis: a systematic review and synthesis of qualitative research. *J Fam Plann Reprod Health Care* 2015; **41**: 225-234 [PMID: 25183531 DOI: 10.1136/jfprhc-2013-100853]

9 **Laganà AS**, Vitale SG, Granese R, Palmara V, Ban Frangež H, Vrtačnik-Bokal E, Chiofalo B, Triolo O. Clinical dynamics of Dienogest for the treatment of endometriosis: from bench to bedside. *Expert Opin Drug Metab Toxicol* 2017; **13**: 593-596 [PMID: 28537213 DOI: 10.1080/17425255.2017.1297421]

10 **Brockman R**. Medication and transference in psychoanalytically oriented psychotherapy of the borderline patient. *Psychiatr Clin North Am* 1990; **13**: 287-295 [PMID: 2352891 DOI: 10.1093/humrep/det050]

11 **Andres Mde P**, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. *Arch Gynecol Obstet* 2015; **292**: 523-529 [PMID: 25749349 DOI: 10.1007/s00404-015-3681-6]

12 **Mita S**, Shimizu Y, Notsu T, Imada K, Kyo S. Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells. *Fertil Steril* 2011; **96**: 1485-1489.e4 [PMID: 22014880 DOI: 10.1016/j.fertnstert.2011.09.040]

13 **Fischer OM**, Kaufmann-Reiche U, Moeller C, Fuhrmann U. Effects of dienogest on surgically induced endometriosis in rats after repeated oral administration. *Gynecol Obstet Invest* 2011; **72**: 145-151 [PMID: 21985956 DOI: 10.1159/000331642]

14 **Katayama H**, Katayama T, Uematsu K, Hiratsuka M, Kiyomura M, Shimizu Y, Sugita A, Ito M. Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model. *Hum Reprod* 2010; **25**: 2851-2858 [PMID: 20813806 DOI: 10.1093/humrep/deq241]

15 **Caruso S**, Iraci M, Cianci S, Casella E, Fava V, Cianci A. Quality of life and sexual function of women affected by endometriosis-associated pelvic pain when treated with dienogest. *J Endocrinol Invest* 2015; **38**: 1211-1218 [PMID: 26337183 DOI: 10.1007/s40618-015-0383-7]

16 **Angioni S**, Pontis A, Malune ME, Cela V, Luisi S, Litta P, Vignali M, Nappi L. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. *Gynecol Endocrinol* 2020; **36**: 84-86 [PMID: 31311360 DOI: 10.1080/09513590.2019.1640674]

17 **Fawzy M**, Mesbah Y. Comparison of dienogest *vs* triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. *Arch Gynecol Obstet* 2015; **292**: 1267-1271 [PMID: 25990480 DOI: 10.1007/s00404-015-3755-5]

18 **Caruso S**, Iraci M, Cianci S, Vitale SG, Fava V, Cianci A. Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain. *J Pain Res* 2019; **12**: 2371-2378 [PMID: 31536046 DOI: 10.2147/JPR.S207599]

19 **Köhler G**, Faustmann TA, Gerlinger C, Seitz C, Mueck AO. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis. *Int J Gynaecol Obstet* 2010; **108**: 21-25 [PMID: 19819448 DOI: DOI: 10.1016/j.ijgo.2009.08.020]

20 **Takenaka M**, Yano R, Hiraku Y, Shibata M, Hatano K, Yamamoto S, Sato K, Yamamoto K, Morishige K. Exploratory study of pre-surgical medications with dienogest or leuprorelin in laparoscopic cystectomy of endometrial cysts. *J Obstet Gynaecol Res* 2015; **41**: 1234-1239 [PMID: 25833348 DOI: 10.1111/jog.12701]

21 **Tamura H**, Yoshida H, Kikuchi H, Josaki M, Mihara Y, Shirafuta Y, Shinagawa M, Tamura I, Taketani T, Takasaki A, Sugino N. The clinical outcome of Dienogest treatment followed by *in vitro* fertilization and embryo transfer in infertile women with endometriosis. *J Ovarian Res* 2019; **12**: 123 [PMID: 31831028 DOI: 10.1186/s13048-019-0597-y]

22 **Harada T**, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H, Terakawa N. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis--a randomized, double-blind, multicenter, controlled trial. *Fertil Steril* 2009; **91**: 675-681 [PMID: 18653184 DOI: 10.1016/j.fertnstert.2007.12.080]

23 **Strowitzki T**, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. *Hum Reprod* 2010; **25**: 633-641 [PMID: 20089522 DOI: 10.1093/humrep/dep469]

24 **Abdou AM**, Ammar IMM, Alnemr AAA, Abdelrhman AA. Dienogest Versus Leuprolide Acetate for Recurrent Pelvic Pain Following Laparoscopic Treatment of Endometriosis. *J Obstet Gynaecol India* 2018; **68**: 306-313 [PMID: 30065547 DOI: 10.1007/s13224-018-1119-3]

25 **Lang J**, Yu Q, Zhang S, Li H, Gude K, von Ludwig C, Ren X, Dong L. Dienogest for Treatment of Endometriosis in Chinese Women: A Placebo-Controlled, Randomized, Double-Blind Phase 3 Study. *J Womens Health (Larchmt)* 2018; **27**: 148-155 [PMID: 29083258 DOI: 10.1089/jwh.2017.6399]

26 **Strowitzki T**, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. *Eur J Obstet Gynecol Reprod Biol* 2010; **151**: 193-198 [PMID: 20444534 DOI: 10.1016/j.ejogrb.2010.04.002]

27 **Osuga Y**, Fujimoto-Okabe H, Hagino A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. *Fertil Steril* 2017; **108**: 673-678 [PMID: 28911934 DOI: 10.1016/j.fertnstert.2017.07.021]

28 **Harada T**, Kosaka S, Elliesen J, Yasuda M, Ito M, Momoeda M. Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial. *Fertil Steril* 2017; **108**: 798-805 [PMID: 28911925 DOI: 10.1016/j.fertnstert.2017.07.1165]

29 **Klipping C**, Duijkers I, Remmers A, Faustmann T, Zurth C, Klein S, Schuett B. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. *J Clin Pharmacol* 2012; **52**: 1704-1713 [PMID: 22128200 DOI: 10.1177/0091270011423664]

30 **Barbieri RL**. Hormone treatment of endometriosis: the estrogen threshold hypothesis. *Am J Obstet Gynecol* 1992; **166**: 740-745 [PMID: 1536260 DOI: 10.1016/0002-9378(92)91706-g]

31 **Petraglia F**, Hornung D, Seitz C, Faustmann T, Gerlinger C, Luisi S, Lazzeri L, Strowitzki T. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. *Arch Gynecol Obstet* 2012; **285**: 167-173 [PMID: 21681516 DOI: 10.1007/s00404-011-1941-7]

32 **Gerlinger C**, Faustmann T, Hassall JJ, Seitz C. Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials. *BMC Womens Health* 2012; **12**: 9 [PMID: 22515510 DOI: 10.1186/1472-6874-12-9]

33 **Gerlinger C**, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C. Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials. *Health Qual Life Outcomes* 2010; **8**: 138 [PMID: 21106059 DOI: 10.1186/1477-7525-8-138]

34 **Olive DL**. Optimizing gonadotropin-releasing hormone agonist therapy in women with endometriosis. *Treat Endocrinol* 2004; **3**: 83-89 [PMID: 15743104 DOI: 10.2165/00024677-200403020-00003]

35 **Strowitzki T,** Faustmann T, Gerlinger C, Schumacher U, Ahlers C, Seitz C. Safety and tolerability of dienogest in endometriosis: Pooled analysis from the european clinical study program. International journal of women's health 2015; 7: 393-401 [PMID: 25926759 DOI: 10.2147/IJWH.S77202]

36 **Mita S**, Shimizu Y, Sato A, Notsu T, Imada K, Kyo S. Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β. *Fertil Steril* 2014; **101**: 595-601 [PMID: 24289989 DOI: 10.1016/j.fertnstert.2013.10.038]

37 **Maeda N**, Izumiya C, Taniguchi K, Matsushima S, Mita S, Shimizu Y, Fukaya T. Dienogest improves human leucocyte antigen-DR underexpression and reduces tumour necrosis factor-α production in peritoneal fluid cells from women with endometriosis. *Eur J Obstet Gynecol Reprod Biol* 2014; **177**: 48-51 [PMID: 24793935 DOI: 10.1016/j.ejogrb.2014.03.019]

38 **Horie S**, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N. Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production *via* nuclear factor kappa B inactivation in endometriotic stromal cells. *Fertil Steril* 2005; **83**: 1530-1535 [PMID: 15866594 DOI: 10.1016/j.fertnstert.2004.11.042]

39 **Takeuchi A**, Koga K, Miyashita M, Makabe T, Sue F, Harada M, Hirata T, Hirota Y, Fujii T, Osuga Y. Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis. *Eur J Obstet Gynecol Reprod Biol* 2016; **207**: 157-161 [PMID: 27865118 DOI: 10.1016/j.ejogrb.2016.10.053]

40 **Ureyen Ozdemir E**, Adali E, Islimye Taskin M, Yavasoglu A, Aktug H, Oltulu F, Inceboz U. Effects of ranibizumab and zoledronic acid on endometriosis in a rat model. *Arch Gynecol Obstet* 2021 [PMID: 34081204 DOI: 10.1007/s00404-021-06104-9]

41 **Turner RT**, Riggs BL, Spelsberg TC. Skeletal effects of estrogen. *Endocr Rev* 1994; **15**: 275-300 [PMID: 8076582 DOI: 10.1210/edrv-15-3-275]

**Footnotes**

**Conflict-of-interest statement:** The authors deny any conflict of interest for this manuscript.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** June 16, 2021

**First decision:** July 6, 2021

**Article in press:** August 20, 2021

**Specialty type:** Obstetrics and gynecology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Rakhshan V **S-Editor:** Liu M **L-Editor:** Wang TQ **P-Editor:** Ma YJ


**Figure Legends**




**Figure 1 Flowchart of study selection process.**

****


**Figure 2 Risk of bias summary of randomized controlled trials.**

****

**Figure 3 Change in visual analogue scale scores and supportive analgesic medication.** A: Forest plot showing dienogest *vs* other intervention (GnRH-a and placebo) in the outcomes of changes in endometriosis related pain measured on visual analogue scale; B: Forest plot showing dienogest *vs* placebo in the outcome of supportive analgesic medication intake changes at the end of treatment. CI: Confidence interval.



**Figure 4 Changes in bone mineral density and serum estradiol.** A: Forest plot showing dienogest *vs* other intervention (GnRH-a and placebo) in the outcomes of percent change in bone mineral density; B: Forest plot showing dienogest *vs* placebo in the change of serum estradiol at the end of treatment. CI: Confidence interval.



**Figure 5 Incidence of headache and hot flushes.** A: Forest plot showing dienogest *vs* other intervention (GnRH-a and placebo) in the incidence of headache; B: Forest plot showing dienogest *vs* other intervention (GnRH-a and placebo) in the incidence of hot flushes.

**Table 1 Characteristics of the studies included in the Meta-analysis**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Country** | **Blind** | **Duration** | **Intervention** | **Sample size** | **Efficacy assessments** | **Safety assessments** |
| Harada *et al*[22], 2009 | RCT | Japan | Double-blind | 24 wk | 2 mg/d DNG  *vs*  900 μg/d buserelin | 137/134 | VAS | BMD change  Hot flashes  Headache |
| Strowitzki *et al*[23], 2010 | RCT | Germany  Austria  Spain Poland Italy Portugal | Open-label | 24 wk | 2 mg/d DNG  *vs*  3.75 mg/4wk leuprolide | 124/128 | VAS | Hot flashes  Headache |
| Abdou *et al*[24], 2018 | RCT | Egypt | Open-label | 12 wk | 2 mg/d DNG  *vs*  3.75 mg/4 wk leuprolide | 130/131 | VAS | Hot flashes  Headache |
| Lang *et al*[25], 2018 | RCT | China | Double-blind | 24 wk | 2 mg/d DNG *vs* placebo | 130/132 | VAS  SAM intake | BMD change  E2 |
| Strowitzki *et al*[26], 2010 | RCT | Germany  Italy  Ukraine | Double-blind | 12 wk | 2 mg/d DNG *vs* placebo | 102/96 | SAM intake | BMD change  E2  Headache |
| Osuga *et al*[27], 2017 | RCT | Japan | Double-blind | 16 wk | 2 mg/d DNG *vs* placebo | 34/33 | VAS  SAM intake | E2  Hot flashes |
| Harada *et al*[28], 2017 | RCT | Japan | DNG: Un-blind  Placebo: Blind | 24 wk | 2 mg/d DNG *vs* placebo | 53/129 | VAS |  |

EM: Endometriosis; AD: Adenomyosis; SAM: Supportive analgesic medication; BMD: Bone mineral density; E2: Serum estradiol.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**